Ipamorelin releases a clean pulse of growth hormone — without the cortisol and prolactin that older peptides triggered.

The short version

Ipamorelin is a small lab-made peptide — a chain of just five amino-acid building blocks. Its one job is to tell the pituitary gland (a pea-sized gland at the base of the brain) to release a short burst of growth hormone, or GH. What made it notable when it was first described in 1998 is selectivity: it nudges GH up without also raising stress hormones like cortisol and prolactin, which the older peptides in its family did ^[1].

People in research-use communities pair it with related peptides and report better sleep and faster recovery — but those are personal accounts, not proof, and what people report (including the downsides) is laid out plainly on the effects page. The honest state of the science: the animal data is consistent, the single human trial that tested whether it treats anything failed ^[3], and it has never been approved as a drug anywhere. This site reads the published record and cites every number.

What "ipamorelin" actually is

Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a wholly synthetic pentapeptide — five amino acids strung together in a lab, never found in the human body. It works by mimicking ghrelin, the hormone your gut releases when you are hungry, at a docking site on pituitary cells called the GHS-R1a receptor (the "growth hormone secretagogue receptor") ^[1].

When ipamorelin docks there, the cell fires off a pulse of growth hormone. That is the entire mechanism. It belongs to a family called growth-hormone-releasing peptides, or GHRPs, and it was engineered from an earlier member (GHRP-1) by trimming two amino acids out of the middle ^[1].

A note on the domain name: "script" is slang for a prescription, but ipamorelin is not a prescribable, approved medicine. No doctor can write a script for an approved ipamorelin product, because no regulator has ever approved one. This is a Ipamorelin research digest, not a clinic and not a pharmacy.

The signature finding: a GH pulse, and nothing else

In the 1998 founding study, ipamorelin released GH as potently as the older peptide GHRP-6 in rat pituitary cells, anaesthetised rats, and conscious pigs (pig ED50 = 2.3 nmol/kg, versus 3.9 nmol/kg for GHRP-6) — yet it did not raise the stress hormones ACTH or cortisol above baseline, even at doses more than 200 times higher than the dose needed to release GH ^[1]. That clean separation is its defining trait and the reason it is still studied a quarter-century later.

Downstream of that GH pulse sits IGF-1 (insulin-like growth factor 1), a liver-made messenger that carries out many of GH's longer-term effects. Importantly, IGF-1 was not reliably raised in the short rodent studies — a 15-day rat bone-growth study increased the bone growth rate without any measurable change in total IGF-1 ^[4]. The pulse is real; whether it sustains into a lasting IGF-1 rise depends on the protocol, and that nuance is covered in how it works.

What the human evidence shows — and where it stops

Human data is thin and, for treating disease, largely negative. A pharmacology study in eight healthy men per dose level mapped its kinetics cleanly: dose-proportional, a terminal half-life of roughly 2 hours, and a single GH pulse peaking about 40 minutes after dosing ^[2]. That is solid, but it only describes how the body handles the peptide — not whether it helps anyone.

The one trial that tested benefit was a Phase 2 study in 114 patients recovering from bowel surgery. It missed its main goal: time to the first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that could have been chance (p=0.15) ^[3]. After that, clinical development stopped. The most recent published work is animal research — a 2024 ferret study where ipamorelin cut chemotherapy-driven weight loss by about 24% but had no anti-nausea effect ^[5]. That is the real shape of the evidence: a well-characterised mechanism, a clean pulse, and an unfinished clinical story.

How to read this site

Every page leads with the finding and cites it. Research covers the mechanism, the key studies, and the CJC-1295 combination. How it works walks through the GH-axis biology in plain English and compares ipamorelin with sermorelin and tesamorelin. Benefits collects what the studies and the research-use community report. Effects is the honest accounting — upsides, downsides, and who has a reason to be cautious. Dosing pages describe only what was given to which species in which study; this site never tells a person to take anything. The full citation list, with DOIs and PubMed links, lives on Ipamorelin references.